Literature DB >> 10190269

Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.

R G Miller1.   

Abstract

Although there is no truly effective disease-specific therapy for any of the motor neuron diseases, rapid progress in our understanding of the pathophysiology of some of these disorders is being made. In addition to progress in neuroscience, clinical trials of agents that appear to slow the progress of at least one of these diseases, amyotrophic lateral sclerosis, are beginning to show promising results. The first clinical trials in spinal muscular atrophy are currently underway. A number of other developments have raised the quality of clinical trials, which should improve their productivity and efficiency in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190269     DOI: 10.1177/088307389901400308

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

Review 1.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

Review 2.  Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2013-08-09       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.